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Abstract
Aims/hypothesis Evidence that glucose-dependent insulinotropic peptide (GIP) and/or the GIP receptor (GIPR) are involved in
cardiovascular biology is emerging. We hypothesised that GIP has untoward effects on cardiovascular biology, in contrast to
glucagon-like peptide 1 (GLP-1), and therefore investigated the effects of GIP and GLP-1 concentrations on cardiovascular
disease (CVD) and mortality risk.
Methods GIP concentrations were successfully measured during OGTTs in two independent populations (Malmö Diet Cancer–
Cardiovascular Cohort [MDC-CC] and Prevalence, Prediction and Prevention of Diabetes in Botnia [PPP-Botnia]) in a total of
8044 subjects. GLP-1 (n = 3625) was measured in MDC-CC. The incidence of CVD and mortality was assessed via national/
regional registers or questionnaires. Further, a two-sample Mendelian randomisation (2SMR) analysis between the GIP pathway
and outcomes (coronary artery disease [CAD] and myocardial infarction) was carried out using a GIP-associated genetic variant,
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rs1800437, as instrumental variable. An additional reverse 2SMR was performed with CAD as exposure variable and GIP as
outcome variable, with the instrumental variables constructed from 114 known genetic risk variants for CAD.
Results In meta-analyses, higher fasting levels of GIP were associated with risk of higher total mortality (HR[95% CI] = 1.22
[1.11, 1.35]; p = 4.5 × 10−5) and death from CVD (HR[95% CI] 1.30 [1.11, 1.52]; p = 0.001). In accordance, 2SMR analysis
revealed that increasing GIP concentrations were associated with CAD and myocardial infarction, and an additional reverse
2SMR revealed no significant effect of CAD on GIP levels, thus confirming a possible effect solely of GIP on CAD.
Conclusions/interpretation In two prospective, community-based studies, elevated levels of GIP were associated with greater
risk of all-cause and cardiovascular mortality within 5–9 years of follow-up, whereas GLP-1 levels were not associated with
excess risk. Further studies are warranted to determine the cardiovascular effects of GIP per se.
Keywords Cardiovascular . Cardiovascular events . Coronary artery disease . GIP . GLP-1 . Glucagon-like peptide 1 .
Glucose-dependent insulinotropic peptide .Mendelian randomisation .Mortality
Abbreviations
CAD Coronary artery disease
CVD Cardiovascular disease
FPG Fasting plasma glucose
GIP Glucose-dependent insulinotropic polypeptide
GIPR GIP receptor
GLP-1 Glucagon-like peptide-1
IVW Inverse variance weighted method
MDC-CC Malmö Diet and
Cancer–Cardiovascular Cohort
MR Mendelian randomisation
OPN Osteopontin
PPP-Botnia Prevalence, Prediction and Prevention
of Diabetes in Botnia
SBP Systolic BP
2SMR Two-sample Mendelian randomisation
Introduction
The enteroendocrine peptide glucose-dependent insulinotropic
polypeptide (GIP) and proglucagon-derived peptides, such as
glucagon-like peptide-1 (GLP-1), were classically viewed as
regulators of islet function, nutrient absorption, appetite and
energy homeostasis [1]. The observation that the G-protein-
coupled receptors, through which these regulatory peptides
exert their effects, are widely expressed in the cardiovascular
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system has triggered a lot of interest in their translational rele-
vance beyond metabolic control [2].
Both experimental and clinical data, such as the outcomes
from the LEADER, SUSTAIN-6, HARMONYand REWIND
trials, support therapeutic benefits of GLP-1 receptor agonists
with regards to cardiovascular outcomes in type 2 diabetes
[3–7]. Further, a missense variant in the gene encoding the
GLP-1 receptor has been associated with protection against
heart disease [8]. While the bulk of the studies published so
far have focused on GLP-1, GIP has received less attention.
Data from our laboratory demonstrated that fasting GIP
concentrations were significantly higher in individuals with a
history of cardiovascular disease (CVD) than in those without,
and that GIP receptor (GIPR) gene mRNA expression is higher
in the arterial wall of individuals with symptoms of CVD [9].
Moreover, a common variant in GIPR (rs10423928), which is
in complete linkage disequilibrium with rs1800437, associates
with increased risk of stroke in individuals with type 2 diabetes
and, recently, Ussher et al. demonstrated that reduction in GIPR
signalling is linked to ischaemic cardioprotection in mice [10].
Thus, evidence that GIP and/or GIPR are involved in cardio-
vascular biology is emerging. In light of these findings, we
explored whether circulating levels of GIP (and GLP-1) are
associated with cardiovascular death and total mortality risk
in two large, population-based cohorts. We also performed a
two-sample Mendelian randomisation (2SMR) analysis using
the GIPR variant rs1800437 previously associated with
features of the metabolic syndrome and CVD [11] as an instru-
mental variable to study the effect of increased GIP levels on
coronary artery disease (CAD) and myocardial infarction.
Furthermore, a 2SMR analysis in a reverse direction from
CAD to GIP was performed, using 114 known genetic risk
variants for CAD as instrumental variables.
Methods
Prevalence, Prediction and Prevention of Diabetes
in Botnia study
The Prevalence, Prediction and Prevention of Diabetes–
Botnia (PPP-Botnia) study is a population-based study in
western Finland started in 2004 to obtain estimates of preva-
lence and risk factors for type 2 diabetes, impaired glucose
tolerance, impaired fasting glucose and the metabolic
syndrome in the adult population. Participants were randomly
recruited from the national Finnish Population Registry to
represent 6–7% of the population in the 18–75 year age range
(mean age 51 ± 17 years) [12]. Altogether, 5208 individuals
participated in the study (54.7% of those invited). A follow-up
study was conducted between 2011 and 2015, in which 3870
(74.3%) individuals participated. After exclusion of individ-
uals with partially missing data, 4572 individuals remained for
analysis of fasting GIP and 4398 for post-challenge GIP (see
electronic supplementary material [ESM] Fig. 1). The number
of individuals with diabetes included in analysis was 307 at
the basal visit and 284 at the re-investigation visit. Diagnosis
of diabetes was confirmed from participants’ records or based
on fasting plasma glucose concentration ≥ 7.0 mmol/l and/or
post-challenge glucose ≥ 11.1 mmol/l. The participants gave
their written informed consent and the study protocol was
approved by the Ethics Committee of Helsinki University
Hospital, Finland.
Malmö Diet and Cancer–Cardiovascular Cohort,
Sweden
Between 1991 and 1996, a prospective, population-based study,
the Malmö Diet and Cancer study, was conducted in the city of
Malmö, Sweden, including questionnaires, blood sample dona-
tions and anthropometrical measurements at the baseline exam-
ination (n= 30,447). All people born in the years 1926–1945 and
living in Malmö were invited to participate. To study cardiovas-
cular risk factors, a sample of the study population (n= 6103)
was randomised into a substudy, the Malmö Diet and Cancer–
Cardiovascular Cohort (MDC-CC) [13]. During 2007–2012, a
new clinical examination was performed (n = 3734) within the
MDC-CC,with the addition ofOGTT [14]. A schematic descrip-
tion of the study population is presented in ESM Fig. 2. Fasting
blood samples were collected from 3692 individuals (fastingGIP
available in n= 3479). Four-hundred-and-forty-nine individuals
did not perform the complete OGTT (386 with previously
known diabetes, 63 for various reasons), resulting in post-
challenge (2 h) blood samples available in 3243 individuals
(post-challenge GIP available in n = 3070). The characteristics
of non-attendees at the re-examination have been described else-
where [13]. The participants gave their written informed consent
and the study protocol was approved by the Ethical Review
Board, Lund, Sweden.
Genotyping
In both cohorts, information on genotype rs1800437 was
obtained from genome-wide association study data performed
at the Broad genotyping faci l i ty using Il lumina
OmniExpressExome BeadChip v1.0 B (MDC-CC, n = 3344)
or Illumina HumanExome BeadChip v1.0 (PPP-Botnia, n =
4905). The call rate was >99.9% and the SNP was in Hardy–
Weinberg equilibrium in both cohorts.
Clinical assessment
PPP-Botnia TwoBP recordingswere obtained from the right arm
of a sitting person after 30 min of rest and their mean value was
calculated. If there was more than 5 mmHg difference between
Diabetologia (2020) 63:1043–1054 1045
the two recordings, the recording was repeated. BMI was calcu-
lated as weight (kg) divided by the square of the height (m).
MDC-CC BP was obtained after 10 min of rest in the supine
position. BMI was calculated as weight (kg) divided by the
square of the height (m).
OGTT In both cohorts, a 75 g OGTT, the most appropriate meth-
od for the clinical assessment of glucometabolic status [14], was
performed after an overnight fast. The OGTT was performed
according to same standardised protocol in both cohorts (indi-
viduals with known diabetes did not undergo an OGTT).
Laboratory assays
For both PPP-Botnia and MDC-CC participants, GIP was
analysed by the same laboratory using the following proce-
dure: during OGTT, blood samples were drawn in order to
analyse GIP at 0 and 120 min. Serum GIP was analysed using
Millipore’s Human GIP Total ELISA (Merck Millipore,
Darmstadt, Germany; no. EZHGIP-54 K; minimum detection
level 1.65 pmol/l, intra- and inter-assay CV 1.8–6.1% and 3–
8.8%, respectively) [15].
PPP-Botnia Serum insulin was measured by an AutoDelfia
fluoroimmunometric assay (PerkinElmer, Waltham, MA,
USA). Fasting plasma glucose was analysed using the
HemoCue Glucose System (HemoCue, Ängelholm, Sweden).
Serum total cholesterol, HDL-cholesterol and triacylglycerol
concentrations were measured first on a Cobas Mira analyser
(Hoffman-La Roche, Basel, Switzerland) and LDL-cholesterol
concentrations were calculated using the Friedewald formula.
Since January 2006, total cholesterol, LDL-cholesterol, HDL-
cholesterol and triacylglycerol concentrations have been
measured using an enzymatic method (Konelab 60i analyser;
Thermo Electron Oy, Vantaa, Finland).
Table 1 Characteristics of the study population within quartiles of GIP plasma concentrations in PPP-Botnia
Characteristic Total Q1 Q2 Q3 Q4
Fasting GIP
No. of participants 4572 1128 1163 1157 1124
Age, years 49.7 ± 15.8 48.0 ± 15.6 49.5 ± 15.7 50.9 ± 15.9 50.4 ± 15.7
Female sex 2421 (53.0) 650 (57.6) 607 (52.2) 615 (53.3) 549 (48.8)
BMI, kg/m2 26.5 ± 4.4 26.1 ± 4.5 26.4 ± 4.1 26.5 ± 4.3 27.0 ± 4.8
Fasting GIP, pmol/l 31.7 (21.7–46.1) 16.6 (13.4–19.2) 26.7 (24.2–29.3) 37.9 (34.8–41.8) 61.4 (52.8–77.1)
Fasting insulin, pmol/l 38.2 (26.1–56.5) 36.3 (25.1–52.7) 36.1 (25.8–53.1) 38.5 (25.8–57.4) 42.8 (28.3–68.3)
FPG, mmol/l 5.4 ± 0.9 5.4 ± 0.7 5.4 ± 0.8 5.4 ± 0.8 5.5 ± 1.4
SBP, mmHg 133.6 ± 19.3 131.4 ± 18.5 133.0 ± 18.7 134.6 ± 20.3 135.3 ± 19.6
LDL-cholesterol, mmol/l 3.3 (2.6–3.9) 3.2 (2.6–3.8) 3.2 (2.6–3.9) 3.3 (2.7–4.0) 3.3 (2.7–3.9)
HDL-cholesterol, mmol/l 1.37 (1.13–1.65) 1.40 (1.16–1.66) 1.40 (1.14–1.68) 1.37 (1.13–1.65) 1.33 (1.10–1.62)
Diabetes 272 (5.9) 37 (3.3) 50 (4.3) 70 (6.1) 115 (10.3)
Number of events (total mortality) 154 (3.0) 26 36 36 56
GIPR rs1800437, MAF 0.28 0.33 0.27 0.27 0.24
Post-challenge GIP
No. of participants 4398 1034 1104 1131 1129
Age, years 49.6 ± 15.7 45.6 ± 15.1 47.0 ± 15.7 50.3 ± 15.3 55.0 ± 15.0
Female sex 2326 (52.9) 414 (40.0) 518 (46.9) 625 (55.3) 769 (68.1)
BMI, kg/m2 26.4 ± 4.4 26.7 ± 4.7 26.4 ± 4.4 26.3 ± 4.3 26.2 ± 4.1
Post-challenge GIP, pmol/l 178.3 (131.5–237.4) 100.1 (82.3–114.3) 153.5 (140.7–163.4) 202.9 (188.7–217.8) 294.1 (259.7–349.5)
Post-challenge insulin, pmol/l 168.8 (100.0–284.0) 126.4 (63.2–222.9) 156.9 (93.1–267.4) 183.3 (111.8–297.9) 200.0 (129.9–327.0)
Post-challenge glucose, mmol/l 5.5 ± 2.2 5.3 ± 2.5 5.5 ± 2.2 5.4 ± 1.9 5.8 ± 2.3
SBP, mmHg 133.3 ± 19.0 132.4 ± 18.5 131.5 ± 18.1 134.0 ± 19.6 135.1 ± 19.6
LDL-cholesterol, mmol/l 3.3 (2.6–3.9) 3.2 (2.5–3.7) 3.2 (2.6–3.8) 3.4 (2.8–4.0) 3.5 (2.8–4.2)
HDL-cholesterol, mmol/l 1.38 (1.14–1.66) 1.35 (1.12–1.60) 1.36 (1.13–1.64) 1.36 (1.13–1.63) 1.43 (1.18–1.73)
Diabetes 194 (4.4) 61 (5.9) 40 (3.6) 37 (3.3) 56 (5.0)
No. of events (total mortality) 130 26 24 32 48
GIPR rs1800437, MAF 0.28 0.32 0.28 0.27 0.24
Values are expressed as mean ± SD, median (25th–75th interquartile range) or n (%)
MAF, minor allele frequency; Q1, quartile with the lowest values; Q4, quartile with the highest values
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MDC-CCDuring OGTT, blood samples were drawn in order to
analyse GLP-1 at 0 and 120 min. Total plasma GLP-1 concen-
trations (intact GLP-1 and the metabolite GLP-1 9–36-amide)
were determined radioimmunologically (minimum detection
limit 1 pmol/l; intra- and inter-assay CV <6.0% and <15%,
respectively). Identical quality controls and batches for all
reagents in each analysis set were used in a consecutive
sample analysis during 2 months [15]. Fasting plasma glucose
was analysed using the HemoCue Glucose System. Serum
insulin was assayed with Dako ELISA kit (K6219, Dako,
Stockholm, Sweden; minimum detection level 3 pmol/l,
intra- and inter-assay CV 5.1–7.5% and 4.2–9.3%, respective-
ly) at the Department of Clinical Chemistry, Malmö
University Hospital. HDL-cholesterol was analysed according
to standard procedures at the Department of Clinical
Chemistry, University Hospital Malmö. LDL-cholesterol
was calculated according to the Friedewald formula.
Classification of endpoints
PPP-Botnia Mortality data were obtained from death certifi-
cates through the national registry for Causes of Death
(Statistics Finland) until the end of 2014. Endpoints were
defined on the basis of ICD10 codes (http://apps.who.int/
classifications/icd10/browse/2016/en). Incidence and
prevalence of CVD was based on a questionnaire completed
by the participants at the basal and follow-up visits (for
questionnaire and definitions, see ESM Methods).
Death from myocardial infarction was defined by ICD10
codes I212, I214, I219 and stroke by ICD10 codes I601, I610,
I619, I620, I630, I634, I635 and I639. Death from CVD was
defined by code groups I110, I119, I120, I212, I214, I219,
I250, I251, I258, I259, I260, I269, I350, I420, I48, I601,
I610, I619, I620, I630, I634, I635, I639, I713 and I693.
Table 2 Characteristics of the study population within quartiles of GIP plasma concentrations in MDC-CC
Characteristic Total Q1 Q2 Q3 Q4
No. of participants 3479 871 870 867 871
Fasting GIP
Age, years 72.4 ± 5.6 71.6 ± 5.4 72.5 ± 5.6 72.8 ± 5.6 72.9 ± 5.6
Female sex 2184 (59.1) 523 (60) 503 (57.9) 494 (57.1) 522 (59.9)
BMI, kg/m2 26.9 ± 4.4 26.4 ± 3.9 26.6 ± 4.0 26.8 ± 4.4 27.8 ± 5.0
Fasting GIP, pmol/l 41.2 (30.4–56.8) 24.5 (20.3–27.6) 35.9 (33.2–38.3) 47.6 (44.4–51.5) 72.9 (63.3–89.3)
Fasting insulin, pmol/l 53.5 (37.5–77.1) 47.9 (34.7–66.0) 50.0 (35.4–72.2) 54.2 (38.9–77.1) 65.3 (44.4–93.1)
FPG, mmol/l 5.9 (5.4–6.5) 5.8 (5.3–6.3) 5.8 (5.4–6.4) 5.9 (5.4–6.5) 6.1 (5.5–6.8)
SBP, mmHg 143 ± 18 141 ± 17 144 ± 19 144 ± 18 144 ± 20
LDL-cholesterol, mmol/l 3.3 (2.6–3.9) 3.4 (2.8–4.0) 3.3 (2.7–3.9) 3.2 (2.6–3.9) 3.1 (2.4–3.8)
HDL-cholesterol, mmol/l 1.4 (1.1–1.7) 1.4 (1.1–1.7) 1.4 (1.1–1.7) 1.4 (1.1–1.7) 1.3 (1.0–1.6)
Diabetes 170 (4.9) 37 (4.3) 42 (4.8) 45 (5.1) 46 (5.2)
No. of events (total mortality) 346 (10.0) 60 (6.9) 74 (8.5) 88 (10.2) 124 (14.2)
GIPR rs1800437, MAF 0.22 0.27 0.21 0.21 0.20
Post-challenge GIP
No. of participants 3070 768 766 769 767
Age, years 72.4 ± 5.6 71.1 ± 5.6 72.0 ± 5.3 72.8 ± 5.6 73.7 ± 5.5
Female sex 1830 (59.6) 355 (46.2) 425 (55.5) 488 (63.5) 562 (73.3)
BMI, kg/m2 26.6 ± 4.2 27.1 ± 4.2 26.4 ± 3.9 26.5 ± 4.0 26.4 ± 4.4
Post-challenge GIP, pmol/l 222.7 (163.2–293.8) 129.7 (106.4–147.1) 193.0 (178.1–207.0) 253.7 (237.3–272.4) 356.8 (321.0–414.1)
Post-challenge insulin, pmol/l 277.0 (179.9–441.0) 257.6 (171.5–400.7) 266.7 (166.0–427.8) 273.6 (189.6–441.0) 311.1 (191.7–520.1)
Post-challenge glucose, mmol/l 6.8 (5.5–8.2) 6.6 (5.5–8.1) 6.7 (5.4–8.1) 6.8 (5.5–8.32) 7.0 (5.6–8.8)
SBP, mmHg 143 ± 19 143 ± 19 144 ± 19 143 ± 19 143 ± 19
LDL-cholesterol, mmol/l 3.3 (2.7–4.0) 3.3 (2.7–3.9) 3.4 (2.7–4.0) 3.4 (2.7–4.0) 3.3 (2.7–4.0)
HDL-cholesterol, mmol/l 1.4 (1.1–1.7) 1.4 (1.0–1.7) 1.4 (1.1–1.7) 1.4 (1.1–1.7) 1.4 (1.2–1.7)
Diabetes 165 (5.4) 47 (6.2) 38 (4.9) 34 (4.4) 46 (5.9)
No. of events (total mortality) 282 (9.2) 49 (6.4) 66 (8.6) 60 (7.8) 104 (13.6)
GIPR rs1800437, MAF 0.22 0.26 0.23 0.21 0.18
Values are expressed as mean ± SD, median (25th–75th interquartile range) or n (%)
MAF, minor allele frequency; Q1, quartile with the lowest values; Q4, quartile with the highest values
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MDC-CC Swedish personal identification numbers were linked
to national registers (The Swedish Hospital Discharge
Register and The Swedish Cause of Death Register; The
National Board of Health andWelfare) [16] for cardiovascular
endpoint retrieval until the end of 2014. All cardiovascular
endpoints were defined on the basis of ICD8 (http://www.
wolfbane.com/icd/icd8.htm), ICD9 (www.icd9data.com/
2007/Volume1) and ICD10 codes. Coronary events were
defined as acute myocardial infarction, other acute and
subacute forms of ischaemic heart disease, old myocardial
Table 3 Associations of 1 SD of log-transformed fasting GIP and post-challenge GIP with total and cardiovascular mortality risk
Variable PPP-Botnia MDC-CC Meta-analysis
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Fasting GIP
Total mortality
Model 1a 1.29 (1.10, 1.50) 0.001 1.27 (1.14, 1.40) 6.0 × 10−6 1.28 (1.17, 1.39) 4.7 × 10−8
Model 2b 1.19 (1.02, 1.40) 0.029 1.26 (1.13, 1.40) 4.9 × 10−5 1.24 (1.13, 1.35) 3.0 × 10−6
Model 3c 1.21 (1.03, 1.43) 0.025 1.23 (1.09, 1.37) 4.3 × 10−4 1.22 (1.11, 1.35) 4.5 × 10−5
Cardiovascular mortality
Model 1a 1.42 (1.11, 1.83) 0.007 1.24 (1.04, 1.48) 0.019 1.29 (1.12, 1.50) 5.0 × 10−4
Model 2b 1.34 (1.02, 1.76) 0.033 1.23 (1.02, 1.48) 0.029 1.26 (1.08, 1.48) 0.0029
Model 3c 1.41 (1.07, 1.85) 0.015 1.25 (1.03, 1.51) 0.023 1.30 (1.11, 1.52) 0.0012
Post-challenge GIP
Total mortality
Model 1a 0.97 (0.81, 1.17) 0.755 1.24 (1.09, 1.40) 0.001 1.15 (1.03, 1.28) 0.01
Model 2b 1.00 (0.83, 1.20) 0.960 1.27 (1.11, 1.45) 0.001 1.18 (1.06, 1.32) 0.004
Model 3c 1.00 (0.83, 1.22) 0.978 1.23 (1.07, 1.41) 0.003 1.14 (1.02, 1.28) 0.02
Cardiovascular mortality
Model 1a 1.05 (0.76, 1.44) 0.771 1.50 (1.21, 1.85) 2.4 × 10−5 1.32 (1.10, 1.57) 0.0023
Model 2b 1.10 (0.80, 1.53) 0.556 1.56 (1.24, 1.96) 1.7 × 10−4 1.39 (1.16, 1.63) 5.0 × 10−4
Model 3c 1.10 (0.79, 1.52) 0.578 1.51 (1.20, 1.91) 4.9 × 10−4 1.36 (1.13, 1.65) 0.0013
No. of individuals (events) included in analyses for fasting GIP: total mortality in PPP-Botnia n = 4572 (154), in MDC-CC n = 3472 (346) and in meta-
analysis n = 8044 (500); cardiovascular mortality in PPP-Botnia n = 4571 (53), in MDC n = 3472 (120) and in meta-analysis n = 8043 (173). No. of
individuals (events) included in analyses for post-challenge GIP: total mortality in PPP-Botnia n = 4398 (130), in MDC-CC n = 3060 (279) and in meta-
analysis: n = 7458 (409); cardiovascular mortality in PPP-Botnia n = 4398 (46), in MDC-CC n = 2827 (89) and in meta-analyses n = 7225 (135)
aModel 1 is adjusted for age and sex
bModel 2 is adjusted for age, sex, BMI, SBP, fasting or post-challenge glucose, fasting or post-challenge insulin, LDL-cholesterol, HDL-cholesterol and
smoking
cModel 3 is adjusted for lipid-lowering treatment, BP-lowering treatment, diabetes status and educational level on top of covariates in Model 2
a b
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Fig. 1 Total mortality risk in quartiles of fasting GIP. (a) Cumulative
hazard for total mortality over a mean follow-up of 8.8 years for fasting
GIP quartiles in PPP-Botnia (p = 0.001). (b) Cumulative hazard for total
mortality over a mean follow-up of 5.1 years for fasting GIP quartiles
(p = 3 × 10−5) in MDC-CC. Q1, quartile with the lowest values; Q4, quar-
tile with the highest values
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infarction, angina pectoris or other forms of chronic ischaemic
heart disease, and identified using codes 410–414 (ICD8),
410–414 (ICD9) and I21, I252, I20, I251, I253-I259
(ICD10). Angioplasty events were obtained from the
Swedish Coronary Angiography and Angioplasty Register
(SCAAR, Kranskärlsregistret) from Uppsala Clinical
Research Center, Akademiska sjukhuset, Uppsala, Sweden.
Coronary artery bypass grafting was identified through origi-
nal surgery codes of the first incident surgery event. The
following surgery codes were extracted: Op6 (1964–96):
3065, 3066, 3068, 3080, 3092, 3105, 3127, 3158 KKÅ97
(1997–) (including subgroups). Fatal or non-fatal stroke was
defined as subarachnoid haemorrhage, intracerebral haemor-
rhage, occlusion of cerebral arteries, acute (but ill-defined)
cerebrovascular disease or stroke of unknown origin and iden-
tified using codes 430, 431, 434 and 436 (ICD9) and I60, I61,
I63 and I64 (ICD10). Stroke events were extracted from
Stromaregistret and Recidivregistret at the Cardiovascular
epidemiology research group, SUS Malmö, Sweden. Heart
failure was retrieved through codes 427.00, 427.10 and 428.
99 (ICD8), 428 (ICD9) and I50 and I11.0 (ICD10). All-cause
death (or otherwise emigration for censored cases) was iden-
tified through Swedish total population register Statistics
Sweden, The Swedish Tax Agency and The National Board
of Health and Welfare. Death from CVD was identified
through codes ICD9:390–459 and ICD10:I [16–19].
Statistical analysis
All analyses were performed in SPSS v.22.0 (SPSS, Armonk, NY,
USA), except for theMendelian randomisation (MR) analyses and
the meta-analyses, which were performed using R software
version 3.5.2 [20]. The 2SMR analyses were built using
MendelianRandomization [21] and TwoSampleMR [22] pack-
ages. A two-tailed p value < 0.05 was considered significant.
Skewed continuous variables were logarithmically transformed.
Individuals with missing values on covariates were excluded from
respective analysis.
Cox regression models were used to calculate HRs for each 1
SD increment of log-transformed fasting and post-challenge GIP
and GLP-1 concentrations on mortality from CVD and total
mortality risk. Individuals who died from external causes were
censored.
Table 4 Associations of 1 SD of log-transformed fasting GIP and post-
challenge GIP with incident non-fatal cardiovascular events
Variable PPP-Botnia MDC-CC
OR (95% CI) p value HR (95% CI) p value
Fasting GIP
Model 1a 1.33 (1.10, 1.60) 0.003 1.13 (0.98, 1.31) 0.088
Model 2b 1.26 (1.04, 1.52) 0.019 1.06 (0.92, 1.23) 0.406
Model 3c 1.25 (1.03, 1.52) 0.024 1.07 (0.93, 1.24) 0.362
Post-challenge GIP
Model 1a 1.20 (0.98, 1.47) 0.073 0.98 (0.83, 1.14) 0.758
Model 2b 1.24 (1.01, 1.53) 0.040 0.97 (0.82, 1.15) 0.748
Model 3c 1.25 (1.02, 1.54) 0.035 0.97 (0.82, 1.15) 0.708
No. of individuals and incident non-fatal cardiovascular events included
in analyses: for PPP-Botnia n = 3084 (128) and for MDC n = 2708 (202).
The two cohorts were analysedwith different methods (logistic regression
in PPP-Botnia, Cox regression in MDC-CC), since exact time to event
was not known for PPP-Botnia. Because of this, and because endpoints
were defined and recorded differently, no meta-analysis was performed
aModel 1 is adjusted for age and sex
bModel 2 is adjusted for age, sex, BMI, SBP, fasting or post-challenge
glucose, fasting or post-challenge insulin, LDL-cholesterol, HDL-choles-
terol and smoking
cModel 3 is adjusted for lipid-lowering treatment, BP-lowering treatment,
diabetes status and educational level on top of covariates in Model 2
Table 5 MR analyses
Exposure Outcome Method IV β SE p value
Fasting GIPa CAD Wald ratio (2SMR) rs1800437 0.51 0.165 0.002
Fasting GIPa MI Wald ratio (2SMR) rs1800437 0.46 0.186 0.013
Fasting GIPb CAD Wald ratio (2SMR) rs1800437 0.42 0.129 0.001
CADc Fasting GIP IVW 114 SNPs −0.042 0.029 0.148
CADc Fasting GIP MR Egger 114 SNPs −0.039 0.074 0.595
aData from CARDIoGRAMplusC4D for CAD (n = 184,305; 60,801 cases, 123,504 controls) and myocardial
infarction (n = 171,875; 43,676 cases, 128,199 controls)
b Data for CAD from UK Biobank (n = 296,525; 34,541 cases, 61,984 controls)
c Loci from CARDiOGRAMplusC4D and UKBiobank were used for constructing the instrumental variable. The
summary data for the outcome (fasting GIP) was acquired from the MDC-CC cohort. Out of 147 SNPs in
CARDiOGRAMplusC4D and UK Biobank (ESM Table 1) with p < 5 × 10−8 and r2 measure of linkage disequi-
librium <0.2, 116 SNPs were selected with available information in MDC-CC (ESM Table 2). An additional two
SNPs (rs472109, rs4754698) were removed from analysis for being palindromic with intermediate allele
frequencies
IV, instrumental variable; MI, myocardial infarction
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As for analyses of incident non-fatal CVD, the two cohorts
were analysed with different methods (Cox regression in
MDC-CC, logistic regression in PPP-Botnia), since exact time
to event was not known for PPP-Botnia. Because of this, and
because endpoints were defined and recorded differently, no
meta-analysis was performed. Further, in exploratory, cross-
sectional analyses for associations between GIP concentration
and prevalent subtypes of CVD, logistic regression was used to
calculate ORs. Model 1 (adjusted for age and sex) was used for
the primary analysis and further adjusted for relevant physio-
logical covariates in Model 2 (BMI, systolic BP [SBP], fasting
plasma glucose [FPG], fasting insulin, LDL-cholesterol, HDL-
cholesterol and smoking for analyses of fasting GIP, and BMI,
SBP, post-challenge glucose, post-challenge insulin, LDL-
cholesterol, HDL-cholesterol and smoking for analyses of
post-challenge GIP). Further adjustment on top of Model 2
was carried out by entering diabetes status, lipid-lowering treat-
ment (LLT), BP-lowering treatment and educational level into
Model 3. Proportional hazard assumptions were tested using
Schoenfeld residuals. Fixed-effects meta-analysis of mortality
variables was performed in R using the metafor package [23].
A 2SMR was performed with fasting GIP levels as exposure
variable, CAD and myocardial infarction were defined as
outcome variables, and rs1800437 as the instrumental variable.
We applied theWald ratio method as statistical modelling for the
2SMR analysis with a summary data for the outcomes from
CARDIoGRAMplusC4D consortium and UKBiobank. In addi-
tion, to further explore the direction of association between GIP
and CAD, we carried out a reverse 2SMR analysis from CAD to
f a s t i n g G I P. L o c i f r om a m e t a - a n a l y s i s o f
CARDiOGRAMplusC4D and UK Biobank [24] were used for
the exposure summary data and constructing the instrumental
variables. The summary data for the outcome (fasting GIP) was
from the MDC-CC cohort. Out of 147 SNPs in meta-analysis of
CARDiOGRAMplusC4D andUKBiobank (ESMTable 1) with
p value < 5 × 10−8 and r2 measure of linkage disequilibrium
<0.2, 116 SNPs were selected with information also in the
MDC-CC (ESM Table 2). When running MR analysis, SNPs
rs472109 and rs4754698 were removed as their effect alleles
were ambiguous. In total, 114 SNPs were utilised to construct
the instrumental variables for 2SMR from CAD to fasting GIP.
The inverse variance weighted (IVW)method, which is a widely
accepted approach for 2SMR analyses with several SNPs as
instrumental variables, was used for themain analysis. The sensi-
tivity analyses for the pleiotropy effect was performed using the
MR Egger method [25].
Results
Detailed characteristics of the study populations are presented
in Tables 1 and 2.
Total and cardiovascular mortality
Fasting GIP In Cox regression analyses, adjusted for sex and
age (Model 1), each 1 SD increment of log-transformed
fasting GIP concentration was associated with higher total
mortality risk in both cohorts. To determine the extent to
which this was mediated by known risk factors for CVD we
further adjusted the analyses for BMI, FPG, fasting insulin,
SBP, LDL-cholesterol, HDL-cholesterol and smoking (Model
2), and the associations remained significant (Table 3). In
Model 3, diabetes status, lipid-lowering treatment, BP-
lowering treatment and educational level were included on
top of the covariates in Model 2 (Table 3). The cumulative
incidence of total mortality for each quartile of fasting GIP is
shown in Kaplan–Meier plots (Fig. 1a, b).
Increased fasting GIP concentration was also associated
with risk of cardiovascular mortality in all models (Table 3).
Post-challenge GIP Increased GIP concentrations after a stan-
dard OGTT (post-challenge) were associated with higher risk
of total and cardiovascular mortality in a meta-analysis of the
two cohorts in all models. However, the post-challenge asso-
ciations were driven mainly by theMDC-CC cohort (Table 3).
Sensitivity analysis To rule out the possibility that the higher
mortality risk was a result of individuals being diabetic and
hence contributing to a larger extent to total mortality, analy-
ses were carried out on associations of GIP and risk of mortal-
ity, as well as cardiovascular mortality, in both cohorts exclud-
ing individuals with prevalent diabetes. The associations
between GIP and mortality risk essentially remained
unchanged (ESM Results, ESM Tables 3–5).
Incident non-fatal cardiovascular events
Fasting GIP Next, we analysed associations between GIP
concentrations and incident, non-fatal CVD. Fasting GIP
concentration was associated with incident CVD during a
mean follow-up of 8.8 years in all models in PPP-Botnia. In
MDC-CC, fasting GIP was not associated with higher risk of
incident non-fatal CVD (Table 4).
Post-challenge GIP The post-challenge GIP concentration was
associated with non-fatal incident CVD in PPP-Botnia. In
MDC-CC, the associations were not significant (Table 4).
A cross-sectional, exploratory analysis of GIP concentra-
tions and CVD prevalence is presented in ESM Results.
Fasting and post-challenge GLP-1 Corresponding analyses
were performed for GLP-1 in 3625 subjects but no significant
associations were observed for either fasting or post-challenge
levels of GLP-1 and mortality risk, or CVD subgroups in the
1050 Diabetologia (2020) 63:1043–1054
MDC-CC study (ESM Table 6). GLP-1 was not measured at
the basal visit in the PPP-Botnia cohort.
MR analyses
We performed a 2SMR analysis byWald ratio method between
GIP levels as exposure and CAD (n = 184,305; 60,801 cases,
123,504 controls) and myocardial infarction (n = 171,875;
43,676 cases, 128,199 controls) as outcome variables in
CARDIoGRAMplusC4D. The same procedure was applied
using data from UK Biobank (CAD: n = 296,525; 34,541
cases, 261,984 controls) [24]. For the exposure (GIP), the
initial sample was 3344 individuals of Swedish ancestry;
4905 individuals of Finnish ancestry were used as the replica-
tion sample [26]. We utilised rs1800437 as the instrumental
variable (see ESM Table 7 for more details). The results show
a significant association between fasting GIP and both CAD
(p = 0.002) and myocardial infarction (p = 0.013), as presented
in Table 5 using CARDIoGRAMplusC4D data, and significant
associations between fasting GIP and CAD using UK Biobank
data (p = 0.001). Further, a reverse 2SMR analysis was carried
out with CAD as exposure and GIP as outcome variable
(Table 5; detailed analysis in ESM Table 8). The non-
significant 2SMR result using the IVW method (p = 0.148)
shows that there is no directional association from CAD to
GIP. There was no evidence of pleiotropy found through the
MR Egger method (Table 5; p = 0.595). The single SNP MR
estimates using each of the 114 SNPs used in the reverse MR
from CAD to GIP can be found in ESM Table 9. The bi-
directionalMR analysis confirmed the possible direction solely
from GIP to CAD.
Discussion
This observational study demonstrates that high plasma
concentration of fasting GIP is associated with higher risk of
total and cardiovascular mortality in two general populations.
Further, using a 2SMR, we demonstrated an association
between increased GIP levels and CAD.
The results from the two studied populations were gener-
ally comparable, with the most consistent effect being the
association between fasting GIP concentration and mortality
risk. The discrepancies found may be explained by the mean
age difference between the two populations (72 years for
MDC-CC vs 50 years for PPP-Botnia), resulting in fewer
outcomes (mortality and cardiovascular mortality) for PPP-
Botnia and there may be differences in the underlying pathol-
ogy of CVD at different ages. Other potential reasons are
differences in population and lifestyle, and the sources and
definitions of CVD in the two studies (self-reported for PPP
and register-derived for MDC-CC). However, the associations
between increased GIP levels and higher risk of CAD/
myocardial infarction were confirmed using the large
CARDIoGRAMplusC4D data in 2SMR analysis.
Recently, Ussher et al. showed that genetic elimination of
GIPR improved survival rate and reduced adverse cardiac
remodelling following experimental myocardial infarction in
mice [10]. Furthermore, epidemiological studies have shown
that fasting GIP concentrations are significantly higher in indi-
viduals with a history of CVD andGIPRmRNA expression is
higher in the arterial wall of individuals with symptoms of
CVD [9]. A suggested mediator of the possible cardiovascular
detrimental effects of GIP is osteopontin (OPN) [9, 27, 28].
OPN regulates synthesis of extracellular matrix and the prolif-
eration and migration of endothelial and vascular smooth
muscle cells during repair and remodelling of blood vessels.
OPN also promotes inflammation and recruitment of
leucocytes to the vessel wall [29]. Accordingly, plasma OPN
has been associated with the presence and severity of CAD in
humans [30]. Notably, GIP stimulation increases OPN expres-
sion in mouse arteries and individuals with symptomatic CVD
have higher plaque expression ofGIPR andOPN (also known
as SPP1) mRNA. Further, GIP infusion increases plasma
concentration of OPN in humans and this effect is strongest
in carriers of the minor allele of the GIPR rs10423928 locus
[9]. Interestingly, there is also a known CAD locus (rs46522)
in the UBE2Z gene, suggested to be mediated by a non-
synonymous coding SNP (rs2291725) in the GIP gene, but
the effect of this locus on GIP function and expression is still
poorly understood [31, 32].While recent experimental data do
not actually support a direct damaging effect of GIP on cardiac
cells [10, 33], recent clinical observations in obese individuals
with hyperglycaemia and insulin resistance show an associa-
tion of increased circulating GIP levels with biomarkers of
chronic low-grade inflammation (this, in turn, might facilitate
CVD) [34].
The MR associations between GIP and CAD shown in our
study indicate a direct role for GIPR signalling in the path-
ways leading to these endpoints, although we cannot conclude
that all of the risk increase observed in this study is due to
direct effects of GIP on the cardiovascular system. The risk
increase for death may, as an example, be mediated by
unhealthy fat distribution, independent of insulin levels, that
is associated with higher GIP release, or by promotion of
obesity [35, 36]. However, our analyses were adjusted for
BMI, implicating other pathways. Another possibility is that
the association is mediated by effects on glucose homeostasis
and risk of diabetes. This was addressed by adjusting for
fasting glucose and insulin values in Model 2 and addition
of diabetes status in Model 3. We also did a set of analyses
wherein we excluded all diabetic individuals (prevalent and
incident diabetes cases) in the MDC-CC cohort (ESM
Tables 3–5), with associations between GIP and mortality risk
essentially unchanged. In the PPP-Botnia cohort, the diabetes
status of individuals who did not attend the follow-up visit
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could not be determined. Instead, we analysed risk of incident
and total CVD in individuals who were normoglycaemic both
at baseline and at follow-up and found that all associations
remained in this smaller subset (ESM Table 4). A third possi-
bility is that part of the associations could be due to unmea-
sured covariates.
The LEADER, SUSTAIN-6, HARMONY and REWIND
studies [3–7] found lower rates of cardiovascular events
among high-risk individuals with type 2 diabetes treated with
the GLP-1 analogues liraglutide, semaglutide, albiglutide and
dulaglutide, respectively, vs placebo. In our study, neither
fasting nor post-challenge GLP-1 concentrations were associ-
ated with the risk of CVD or death, nor did we find any
protective effects of GLP-1 on mortality and CVD risk. This
discrepancy could be due either to the different populations
studied (e.g. the PPP-Botnia and MDC-CC are population
cohorts consisting of only 5.9% and 4.4% individuals with
diabetes, respectively, in contrast to the LEADER and
SUSTAIN trial in which only diabetic individuals were stud-
ied) or, even more likely, to different concentrations of GLP-1
as the cardioprotective effects of GLP-1 agonists/analogues
demonstrated earlier are attributed to pharmacologically
induced, supraphysiological levels of GLP-1 in contrast to
the normal, physiological GLP-1 levels in our study.
Strength and limitations
The use of well-characterised, prospective cohorts with many
participants and a relatively long follow-up time is a signifi-
cant strength of the current study. Further, we used nationwide
registers with 100% coverage and high accuracy. We could
not completely exclude confounding effects of unmeasured
covariates linked to GIP levels but tried to minimise
confounders by adjusting for relevant risk factors. Another
strength of this study is the demonstration of an effect of a
functional genetic variant in GIPR on CAD/myocardial
infarction using the MR approach, suggesting an involvement
of the GIP signalling pathway in the pathogenesis of CAD.
We acknowledge that the MR analysis has limitations such
as horizontal pleiotropy. To improve the reliability of our GIP
to CAD/myocardial infarction MR analysis, we considered
the possible confounding phenotypes and tested for their asso-
ciation with our instrumental variable rs1800437, which is
associated with insulin secretion [26, 28, 37], BMI and other
related phenotypes (ESM Tables 10 and 11). These pheno-
types are likely to mediate at least some of the association
between the genetic variant in GIP and CAD (vertical pleiot-
ropy). Because of this, and because the genetic variant affects
both the concentration of GIP and the expression and function
of its receptor (horizontal pleiotropy), the MR effect size esti-
mates should be interpreted with caution. However, using a
genetic variant in GIPR greatly strengthens the evidence that
the association is due to GIP signalling, since there are no
known alternative ligands for the GIPR. For the reverse MR,
there was no evidence of a pleiotropic effect based on MR
Egger analyses (Table 5). Furthermore, the two cohorts
(PPP-Botnia and MDC-CC) differ regarding the mean age of
the participants (those in PPP-Botnia were younger), event-
rate and how endpoints were collected, possibly explaining
the discrepancies in the results presented. Finally, our data
was collected in two Nordic regions, which limits the appli-
cability to other populations.
Conclusion
In two prospective, community-based studies, elevated levels
of GIP were associated with greater risk of all-cause and
cardiovascular mortality within 5–9 years of follow-up,
whereas GLP-1 levels were not associated with excess risk.
Further studies are needed to determine the cardiovascular
effects of GIP per se.
Acknowledgements Open access funding provided by Lund University.
The Knut andAliceWallenberg foundation is acknowledged for generous
support.
Data availability The data that support the findings of this study are avail-
able upon request from the Steering Committee of the Malmö Diet and
C a n c e r s t u d y b y c o n t a c t i n g i t s c h a i r , O . Me l a n d e r
(olle.melander@med.lu.se). Restrictions apply to the availability of these
data, which were used under licence for the current study, and so they are
not publicly available due to ethical and legal restrictions related to the
Swedish Biobanks in Medical Care Act (2002:297) and the Personal Data
Act (1998:204). Data on myocardial infarction have been contributed by
CARDIoGRAMplusC4D investigators and have been downloaded from
http://www.CARDIOGRAMPLUSC4D.ORG. Data on CAD have been
contributed by the CARDIoGRAMplusC4D and UK Biobank
CardioMetabolic Consortium CHD working group.
Funding This work was supported by these Funding sources: grants from
the Swedish Research Council (K2008 – 65X-20 752– 01–3, K2011– 65X-
20 752– 04 – 6, 2010-3490), the Lundströms Foundation, the Swedish
Heart-Lung Foundation (2010–0244; 2013–0249), ALF government grants
(Dnr: 2012/1789), Folkhälsan Research Foundation, Sigrid Jusélius
Foundation, the Finnish Medical Society, the Finnish Diabetes research
Foundation, the Academy of Finland (FiDiPro grant 263401 and project
grant 267882). AJ was funded by Lund University and Region Skåne. MM
and OM were supported by grants from the Swedish Medical Research
Council, the Swedish Heart and Lung Foundation, the Medical Faculty of
Lund University, Skåne University Hospital, the Albert Påhlsson Research
Foundation, the Crafoord Foundation, the Ernhold Lundströms Research
Foundation, the Region Skåne, the Hulda andConradMossfelt Foundation,
the Southwest Skåne Diabetes Foundation, the King Gustaf V and Queen
Victoria Foundation, the Lennart HanssonsMemorial Fund, Knut andAlice
Wallenberg Foundation and the Marianne and Marcus Wallenberg
Foundation. MM was also supported by the Wallenberg Centre for
Molecular Medicine at Lund University. PMN was supported by grants
from the Swedish Medical Research Council, the Swedish Heart and
Lung Foundation, the Medical Faculty of Lund University, Skåne
University Hospital and the Ernhold Lundströms Research Foundation.
EA was supported by grants from the Swedish Research Council (2017–
02688), ALF government grants, Diabetes Wellness Sweden (25–420 PG),
the Swedish Heart and Lung Foundation, the Crafoord Foundation, the
1052 Diabetologia (2020) 63:1043–1054
Swedish Diabetes Foundation, the Novo Nordisk Foundation
(NNF18OC0034408), Bo and Kerstin Hjelt Foundation and the Albert
Påhlsson Research Foundation. The PPP-Botnia study has been financially
supported by grants from the Sigrid Juselius Foundation, Folkhälsan
Research Foundation, Ollqvist Foundation, Nordic Center of Excellence
in Disease Genetics, EU (EXGENESIS, EUFP7-MOSAIC), Signe and
Ane Gyllenberg Foundation, Swedish Cultural Foundation in Finland,
Finnish Diabetes Research Foundation, Foundation for Life and Health in
Finland, Finnish Medical Society, Paavo Nurmi Foundation, Helsinki
University Central Hospital Research Foundation, Perklén Foundation,
Närpes Health Care Foundation and Ahokas Foundation. The study has
also been supported by the Ministry of Education in Finland, Municipal
Health Care Center and Hospital in Jakobstad and healthcare centres in
Vasa, Närpes and Korsholm. MFG was supported by the Swedish Heart
and Lung Foundation (no. 20160872) and the Swedish Research Council
(no. 2014–03352). LMB was supported by The Swedish Society for
Medical Research. SR and JD were supported by grants from the
Ministry of Economy and Competitiveness, Madrid, Spain (Instituto de
Salud Carlos III grants RD12/0042/0009 and PI15/01909) and the
European Commission FP7 Programme, Brussels, Belgium
(EUMASCARA project grant HEALTH-2011-278249, HOMAGE project
grant HEALTH-2012-305507). The funders of the study had no role in
study design, data collection, data analysis, data interpretation or writing
of the report. AJ, MM, EA and LG had full access to the data in the study
and had final responsibility for the decision to submit for publication.
Duality of interest The authors declare that there is no duality of interest
associated with this manuscript.
Contribution statement MM is the guarantor for this manuscript. AJ, NA-
P, MP, OM, MM, LG, EA, PMN, TT, LH, JJH, SST, LMB, RBP, SR, JD
andMFG contributed to the conception of the work and data collection. AJ,
NA-P, PWF, MP, OM, PA, MM, LG, EA and PMN contributed to data
analysis and interpretation. AJ, NA-P, LG, MM, EA, MFG, LMB, JD, SR,
PWF and PMN contributed to drafting the article (MM and EA contributed
equally). All authors contributed to the critical revision of the article. All
authors gave final approval of the version to be published.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in
the article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Mayo KE, Miller LJ, Bataille D et al (2003) International Union of
Pharmacology. XXXV. The glucagon receptor family. Pharmacol
Rev 55(1):167–194. https://doi.org/10.1124/pr.55.1.6
2. Pujadas G, Drucker DJ (2016) Vascular biology of glucagon recep-
tor superfamily peptides: mechanistic and clinical relevance.
Endocr Rev 37(6):554–583. https://doi.org/10.1210/er.2016-1078
3. Marso SP, Poulter NR, Nissen SE et al (2013) Design of the
liraglutide effect and action in diabetes: evaluation of
cardiovascular outcome results (LEADER) trial. Am Heart J
166(5):823–830 e825. https://doi.org/10.1016/j.ahj.2013.07.012
4. Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardio-
vascular outcomes in patients with type 2 diabetes. N Engl J Med
375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141
5. Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide
and cardiovascular outcomes in type 2 diabetes. N Engl J Med
375(4):311–322. https://doi.org/10.1056/NEJMoa1603827
6. Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide
and cardiovascular outcomes in patients with type 2 diabetes and
cardiovascular disease (Harmony Outcomes): a double-blind,
randomised placebo-controlled trial. Lancet 392(10157):1519–
1529. https://doi.org/10.1016/S0140-6736(18)32261-X
7. Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide
and cardiovascular outcomes in type 2 diabetes (REWIND): a
double-blind, randomised placebo-controlled trial. Lancet
394(10193):121–130. https://doi.org/10.1016/S0140-6736(19)
31149-3
8. Scott RA, Freitag DF, Li L et al (2016) A genomic approach to
therapeutic target validation identifies a glucose-lowering GLP1R
variant protective for coronary heart disease. Sci Transl Med
8(341):341ra376. https://doi.org/10.1126/scitranslmed.aad3744
9. Berglund LM, Lyssenko V, Ladenvall C et al (2016) Glucose-
dependent insulinotropic polypeptide stimulates osteopontin
expression in the vasculature via endothelin-1 and CREB.
Diabetes 65(1):239–254. https://doi.org/10.2337/db15-0122
10. Ussher JR, Campbell JE, Mulvihill EE et al (2018) Inactivation of
the glucose-dependent insulinotropic polypeptide receptor
improves outcomes following experimental myocardial infarction.
Cell Metab 27(2):450–460 e456. https://doi.org/10.1016/j.cmet.
2017.11.003
11. Nitz I, Fisher E, Weikert C et al (2007) Association analyses of GIP
and GIPR polymorphisms with traits of the metabolic syndrome.
Mol Nutr Food Res 51(8):1046–1052. https://doi.org/10.1002/
mnfr.200700048
12. Isomaa B, Forsen B, Lahti K et al (2010) A family history of diabe-
tes is associated with reduced physical fitness in the Prevalence,
Prediction and Prevention of Diabetes (PPP)-Botnia study.
Diabetologia 53(8):1709–1713. https://doi.org/10.1007/s00125-
010-1776-y
13. Rosvall M, Persson M, Ostling G et al (2015) Risk factors for the
progression of carotid intima-media thickness over a 16-year
follow-up period: the Malmo Diet and Cancer Study.
Atherosclerosis 239(2):615–621. https://doi.org/10.1016/j.
atherosclerosis.2015.01.030
14. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classifi-
cation of diabetes mellitus and its complications. Part 1: diagnosis
and classification of diabetes mellitus provisional report of a WHO
consultation. Diabet Med 15(7):539–553. https://doi.org/10.1002/
(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
15. Jujic A, Nilsson PM, Persson M et al (2016) Atrial natriuretic
peptide in the high normal range is associated with lower preva-
lence of insulin resistance. J Clin Endocrinol Metab 101(4):1372–
1380. https://doi.org/10.1210/jc.2015-3518
16. (Socialstyrelsen) TNBoHaW (2000) Evaluation of quality of diag-
nosis of acute myocardial infarction, inpatient register 1997 and
1995. Socialstyrelsen, Stockholm [In Swedish]
17. Engstrom G, Jerntorp I, Pessah-Rasmussen H, Hedblad B,
Berglund G, Janzon L (2001) Geographic distribution of stroke
incidence within an urban population: relations to socioeconomic
circumstances and prevalence of cardiovascular risk factors. Stroke
32(5):1098–1103
18. Hammar N, Alfredsson L, Rosen M, Spetz CL, Kahan T, Ysberg
AS (2001) A national record linkage to study acute myocardial
infarction incidence and case fatality in Sweden. Int J Epidemiol
30(Suppl 1):S30–S34
Diabetologia (2020) 63:1043–1054 1053
19. Ingelsson E, Arnlov J, Sundstrom J, Lind L (2005) The validity of a
diagnosis of heart failure in a hospital discharge register. Eur J Heart
Fail 7(5):787–791. https://doi.org/10.1016/j.ejheart.2004.12.007
20. R Core Team (2013) R: a language and environment for statistical
computing. R Foundation for Statistical Computing Vienna.
Available from: http://www.R-project.org/ (accessed 20May 2019)
21. Yavorska OO, Burgess S (2017) MendelianRandomization: an R
package for performing Mendelian randomization analyses using
summarized data. Int J Epidemiol 46(6):1734–1739. https://doi.org/
10.1093/ije/dyx034
22. Hemani G, Zheng J, Elsworth B, et al. (2018) The MR-Base plat-
form supports systematic causal inference across the human
phenome. Elife 7. https://doi.org/10.7554/eLife.34408
23. Viechtbauer W (2010) Conducting meta-analyses in R with the
metafor package. J Stat Software 36(3):48. https://doi.org/10.
18637/jss.v036.i03
24. van der Harst P, Verweij N (2018) Identification of 64 novel genetic
loci provides an expanded view on the genetic architecture of coro-
nary artery disease. Circ Res 122(3):433–443. https://doi.org/10.
1161/CIRCRESAHA.117.312086
25. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG (2017)
Sensitivity analyses for robust causal inference from mendelian
randomization analyses with multiple genetic variants.
Epidemiology 28(1):30–42. https://doi.org/10.1097/EDE.
0000000000000559
26. Almgren P, Lindqvist A, Krus U, et al. (2017) Genetic determinants
of circulating GIP and GLP-1 concentrations. JCI Insight 2(21):
93306. https://doi.org/10.1172/jci.insight.93306
27. Ahlqvist E, Osmark P, Kuulasmaa T et al (2013) Link between GIP
and osteopontin in adipose tissue and insulin resistance. Diabetes
62(6):2088–2094. https://doi.org/10.2337/db12-0976
28. Lyssenko V, Eliasson L, Kotova O et al (2011) Pleiotropic effects of
GIP on islet function involve osteopontin. Diabetes 60(9):2424–
2433. https://doi.org/10.2337/db10-1532
29. Wolak T (2014) Osteopontin - a multi-modal marker and mediator
in atherosclerotic vascular disease. Atherosclerosis 236(2):327–
337. https://doi.org/10.1016/j.atherosclerosis.2014.07.004
30. Ohmori R, Momiyama Y, Taniguchi H et al (2003) Plasma osteo-
pontin levels are associated with the presence and extent of coro-
nary artery disease. Atherosclerosis 170(2):333–337. https://doi.
org/10.1016/s0021-9150(03)00298-3
31. Schunkert H, Konig IR, Kathiresan S et al (2011) Large-scale asso-
ciation analysis identifies 13 new susceptibility loci for coronary
artery disease. Nat Genet 43(4):333–338. https://doi.org/10.1038/
ng.784
32. Chang CL, Cai JJ, Lo C, Amigo J, Park JI, Hsu SY (2011) Adaptive
selection of an incretin gene in Eurasian populations. Genome Res
21(1):21–32. https://doi.org/10.1101/gr.110593.110
33. Hiromura M, Mori Y, Kohashi K et al (2016) Suppressive effects of
glucose-dependent insulinotropic polypeptide on cardiac hypertro-
phy and fibrosis in angiotensin II-infused mouse models. Circ J
80(9):1988–1997. https://doi.org/10.1253/circj.CJ-16-0152
34. Goralska J, Razny U, Polus A et al (2018) Pro-inflammatory gene
expression profile in obese adults with high plasma GIP levels. Int J
Obes 42(4):826–834. https://doi.org/10.1038/ijo.2017.305
35. Moller CL, Vistisen D, Faerch K et al (2016) Glucose-dependent
insulinotropic polypeptide is associated with lower low-density
lipoprotein but unhealthy fat distribution, independent of insulin:
the ADDITION-PRO study. J Clin Endocrinol Metab 101(2):485–
493. https://doi.org/10.1210/jc.2015-3133
36. Morgan LM, Hampton SM, Tredger JA, Cramb R, Marks V (1988)
Modifications of gastric inhibitory polypeptide (GIP) secretion in
man by a high-fat diet. Br J Nutr 59(3):373–380. https://doi.org/10.
1079/bjn19880046
37. Saxena R, Hivert MF, Langenberg C et al (2010) Genetic variation
in GIPR influences the glucose and insulin responses to an oral
glucose challenge. Nat Genet 42(2):142–148. https://doi.org/10.
1038/ng.521
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
1054 Diabetologia (2020) 63:1043–1054
